RP-1828 IMMUcan
The goal is to generate broad molecular (WES, lcWGS and RNAseq) and cellular profiling data (multiplex IF and IMC) of the tumour and its microenvironment from cancer patients integrated with clinical data, to understand how the immune system and tumours interact, and the impact of current therapeutic interventions.
We will collect:
Material available at enrollment in IMMUcan:
- FFPE Tissue: At least one FFPE block or a minimum 15 FFPE slides
- Fresh Frozen (FF) Tissue: Requested when available (for molecular analysis)
- Blood:1 serum tube, 3 ACD tubes, 1 BCT, 1 PAXgene RNA tube, 1 PAXgene DNA tube, 1 EDTA tube
Others: Stool and saliva samples
At follow-up (at progression, but check cohort specificities):
- FFPE Tissue: At least one FFPE block or a minimum 15 FFPE slides (when possible, depending on tissue availability)
- Fresh Frozen (FF) Tissue: requested when available (for molecular analysis)
- Blood: 1 serum tube, 3 ACD tubes, 1 BCT, 1 PAXgene RNA tube, 1 EDTA tube
RP-1759 AYA/TYA
12-29 year-old: Non-Grade 1 Bone and Soft Tissue Sarcoma , High Grade Diffuse Astrocytic Tumors patients
EORTC wants to develop a sequencing project targeting specifically young adults (12 to 29 years old) with rare cancer (with Martin McCabe as study coordinator):
- to understand better the biology of the tumor in this specific population, and compare it to children and adults with similar disease
- to improve the inclusion of young adults into clinical trials.
The pilot study will be focusing on young adults with high grade glioma as well as non-grade 1 bone and soft tissue sarcoma. Patients with initial diagnosis must be recruited prospectively within 6 months of diagnosis. To note, surgical specimen for patients treated with neo-adjuvant therapy can be used. For relapse patients, FFPE sample must be from the latest progression, patient must be alive, patient must be under treatment for the latest progression and not have had a new recurrence in between.
The aim of the pilot phase is to test the infrastructure and our accrual potential in this age group of patients.
For this project, we will collect FFPE tissue available at enrollment to perform molecular analysis (WES, RNAseq and EPIC array) and also implement a central pathology review as well as a molecular tumor board, to bring the clinical knowledge back to the patient and the clinician.
RP-1843 Arcagen
This is a collaborative project between EORTC and EURACAN (with Jean Yves Blay as study coordinator), to perform molecular characterisation of rare cancers patients, using Foundation Medicine tests. The goal of this project is to get a better understanding of the genomic landscape of rare cancers and potentially help define possibilities for targeted treatments/clinical trials for this population.
We will collect at least one FFPE block or freshly cut FFPE slides from an archival block of less than 2 years old or from a freshly collected de novo biopsy performed as per routine care. Samples should contain sufficient tumour and stroma content and/or be large enough to meet DNA/RNA input requirements. If the FFPE sample does not meet the quality and quantity requirement, a blood sample will be required.
RP-1920 BioRadon
The BioRadon project aims at correlating the molecular phenotype of Non Small Cell Lung Cancers to the indoor radon exposure. For this project, 3 new cohorts will open in the coming 6 months to recruit 1323 NSCLC patients.
More information to come.
, next to the green status.
. Please note that your electronic database ORTA password is required for access (protocol 1553).